Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy.
Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy.
复制标题
DOI：
10.1016/j.bbih.2021.100217
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Liu A
中科院分区：
文献类型：
--
作者：
Repajic M;Lai XL;Xu P;Liu A
报告一名有复发性贝尔麻痹病史的患者，在注射第二剂辉瑞 BioNTech COVID-19 疫苗 36 小时后出现贝尔麻痹。患者是一名 57 岁女性，既往有 3 次贝尔麻痹病史。她对泼尼松治疗有反应，并在每次发生后恢复到基线。注射第二剂疫苗后不到 36 小时，患者出现左侧贝尔氏麻痹症。在接下来的 72 小时内，面部下垂变得更加严重。鉴于疫苗生产的加快以及与其生产相关的新颖性，可能还有与副作用和个人反应有关的信息有待发现。由于 Moderna 和辉瑞疫苗试验均将贝尔氏麻痹症报告为医疗不良事件，因此疫苗接种与有症状贝尔氏麻痹症发作之间的关联可能值得进一步研究。
To report a patient with history of recurrent Bell’s Palsy who developed Bell’s Palsy 36 h after the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine. The patient is a 57-year-old female with past medical history of 3 episodes of Bell’s Palsy. She responded to prednisone treatment and returned to her baseline after each occurrence. Less than 36 h following the second dose of the vaccine, the patient developed a left Bell’s Palsy. The facial droop progressed in severity over the next 72 h. Given the expedited production of the vaccine and the novelty associated with its production, there may be information pertaining to side effects and individual response that remain to be discovered. Since both the Moderna and Pfizer Vaccine trials reported Bell’s Palsy as medically attended adverse events, the association between vaccine administration and onset of symptomatic Bell’s Palsy may warrant further investigation.
影响因子：
2.6
作者：
Zhou, WG;Pool, V;Chen, RT
通讯作者：
Chen, RT
影响因子：
158.5
作者：
Mutsch, M;Zhou, WG;Steffen, R
通讯作者：
Steffen, R
影响因子：
2.1
作者：
Dong, Sung Hwa;Jung, Ah Ra;Yeo, Seung Geun
通讯作者：
Yeo, Seung Geun